Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer

In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.

Dr Anita Sveen received the Young Investigator prize at Onkologisk Forum for her research accomplishments

Anita Sveen received the YI prize worth 50,000 NOK at Onkologisk Forum, the annual meeting for oncologists, for her research accomplishments on computational oncology.

Latest publications

Brunsell et al. 2019. High concordance and negative prognostic impact of RAS/BRAF/PIK3CA mutations in multiple resected colorectal liver metastases. Clin. Colorectal Cancer [Online ahead of print] Sveen et al. 2019. Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Ann. Oncol. 30(11): 1682-1685 Miranda et al. 2019. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. PNAS 116(18): 9020-9029 Burocziova et al. 2019. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death. Dis. 10(11): 818
 Eilertsen et al. 2019. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. [Epub ahead of print] All publications